Healthcare
Structure Therapeutics Inc.(GPCR)
Live Price
Offline$44.51
-1.09% today
1Y Change
+106.52%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $2.38B
- Revenue Growth
- 0.0%
- EPS Growth
- -2.6%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Structure Therapeutics Inc. (GPCR) is a Healthcare stock with a market cap of $2.38B and listed on NASDAQ. The stock last traded around $44.51 and up 106.5% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -2.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -2.6%, free cash flow -91.5% with operating margin 0.0% and ROIC -11.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GPCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -2.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.9% | -2.6% | +7.8% |
2026 Feb 26, 2026 | -40.0% | -2.7% | -7.8% | -28.6% |
2025 Nov 6, 2025 | -2.8% | -1.9% | +4.6% | +3.3% |
Benchmark Edge
GPCR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GPCR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GPCR Max Drawdown
-61.74%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GPCR and SPY.
Company Overview
Structure Therapeutics Inc.
NASDAQ Global Market
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
- Leadership
- Raymond C. Stevens
- IPO Date
- Feb 3, 2023
- Employees
- 163
- Street Address
- 611 Gateway Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 628-229-9277
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.6
Growth
- Revenue
- 0.0%
- EPS
- -2.6%
- Free Cash Flow
- -91.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -14.5%
- ROIC
- -11.6%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 24.81
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.